P
POLB
vs
F
FTSE All Share Index
Over the past 12 months, POLB has significantly outperformed FTSE All Share Index, delivering a return of +32% compared to the FTSE All Share Index's 0% growth.
Stocks Performance
POLB vs FTSE All Share Index
Performance Gap
POLB vs FTSE All Share Index
Performance By Year
POLB vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Poolbeg Pharma PLC
Glance View
Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is focused on targeting the medical needs to treat and prevent infectious disease. The firm's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The firm's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The firm is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.
